Overview


According to FutureWise analysis the market for undescended testicle diagnosis in 2023 is US$ 6.11 billion, and is expected to reach US$ 16.03 billion by 2031 at a CAGR of 12.80%.

An undescended testis, also known as Cryptorchidism, is one of the most common malformations of male neonates. The undescended testis (UDT) is the second most common paediatric operating condition after inguinal hernias. In this case, the testis is not in the scrotum by the age of three months due to a failure of normal descent. It is uncommon for boys' testes to descend after three months; five percent have a UDT at birth, one to two percent at three months, and one percent at one year. It is possible to reduce the risk of malignancy and infertility by managing the condition in an appropriate timeframe. According to secondary research, 3-4 percent of full-term baby boys are born with cryptorchidism, a condition in which one or both testicles are not located in the expected place in the scrotum. There is a surge in demand for undescended testicle diagnosis and an increase in the prevalence of undescended testicle among young men driving this growth. In addition to the rise in the demand for undescended testicle diagnosis, the advancement in the healthcare sector, the increase in research and development activities, and the rise in infertility issues are some of the crucial factors driving the undescended testicle market. It might reduce the risk of malignancy or infertility if treated at the appropriate time. Having undescended testicles isn't painful, and your child isn't at risk of any immediate health problems, but you should get them checked by a doctor in case further treatment is needed. An undescended testicle carries an increased risk of developing testicular cancer regardless of whether it is corrected or not. In spite of the fact that the risk is lower after treatment, it is still higher than if both testicles were descended at birth. In some cases, it is difficult to distinguish between an undescended testicle and one with the sliding condition. Children with undescended testes are often best treated by a pediatric urologist who specializes in conditions of the urinary tract system, which includes the testes.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Undescended Testicle Diagnosis Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Undescended Testicle Diagnosis Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Promedon HQ \Cordoba
  • Sebbin
  • Eli Lilly
  • Implantech
  • Coloplastt Corp
  • Baxter
  • Bristol Myers Squibb
  • Pfizer
  • POLYTECH Health
  • Aesthetics GmbH
  • UROMED
  • Teva Pharmaceutical
  • GC Asthetics
  • Rigicon Inc

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • Congenital or Acquired
  • Palpable or Non-Palpable
  • Unilateral or Bilateral

By Diagnosis

  • Laparoscopy
  • Hormone Therpay
  • Open Surgery

By Distribution Channel

  • Clinics
  • Hospitals
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Undescended Testicle Diagnosis Market By Type, By Diagnosis, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Undescended Testicle Diagnosis Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Undescended Testicle Diagnosis Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Undescended Testicle Diagnosis Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Undescended Testicle Diagnosis Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Congenital or Acquired
        2. Palpable or Non-Palpable
        3. Unilateral or Bilateral

  • 8.   Undescended Testicle Diagnosis Market, By Diagnosis Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Laparoscopy
        2. Hormone Therpay
        3. Open Surgery

  • 9.   Undescended Testicle Diagnosis Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Clinics
        2. Hospitals
        3. Others

  • 10.   North America Undescended Testicle Diagnosis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Undescended Testicle Diagnosis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Undescended Testicle Diagnosis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Undescended Testicle Diagnosis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Promedon HQ \Cordoba
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Sebbin
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Eli Lilly
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Implantech
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Coloplastt Corp
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Baxter
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Bristol Myers Squibb
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Pfizer
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. POLYTECH Health & Aesthetics GmbH
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. UROMED
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
         11. Teva Pharmaceutical
          11.1. Company Overview
          11.2. Product Portfolio
          11.3. SWOT Analysis
          11.4. Financial Overview
          11.5. Strategic Overview
         12. GC Asthetics
          12.1. Company Overview
          12.2. Product Portfolio
          12.3. SWOT Analysis
          12.4. Financial Overview
          12.5. Strategic Overview
         13. Rigicon Inc
          13.1. Company Overview
          13.2. Product Portfolio
          13.3. SWOT Analysis
          13.4. Financial Overview
          13.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients